Health Care sector stocks

XLV stock price: $84.99 -2.14% At close on Mar 27th, 2020

Health Care sector definition

The healthcare sector consists of companies that provide medical services, manufacture medical equipment or drugs, provide medical insurance, or otherwise facilitate the provision of healthcare to patients.

Health Care sector is composed of 853 companies with a total market capitalization of $4.95 tn

Health Care companies

Aetna Inc. (AET)

Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions.The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products, including pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. has a collaborative agreement with Community Care Physician Network, LLC to deliver healthcare services in North Carolina. The company was founded in 1853 and is based in Hartford, Connecticut.

  • Industry: Medical Specialities
  • Country: USA
  • Market cap: $66.38 bn
  • 3M gains: +6.47 %
  • Avg. Volume: 12.2 M

Array BioPharma Inc. (ARRY)

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib\u002FGDC-0068 for the treatment of cancer, as well as ASC08\u002FDanoprevir to treat hepatitis C virus. Its drug candidates in Phase II\u002Fregistration trials comprise Larotrectinib\u002FLOXO-101, a PanTrk inhibitor for cancer; Tucatinib\u002FONT-380, a HER2 inhibitor for breast cancer; and Varlitinib\u002FASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A\u002FC-related dilated cardiomyopathy; Motolimod\u002FVTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib\u002FLY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I\u002FII clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $4.81 bn
  • 3M gains: +106.52 %
  • Avg. Volume: 29.0 M

The Medicines Company (MDCO)

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms. The company's approved products include Adenosine, Amiodarone, Esmolol, and Milrinone for acute cardiovascular; Azithromycin and Clindamycin for serious infectious disease; and Haloperidol, Midazolam, Ondansetron, and Rocuronium for surgery and perioperative treatment. Its research and development stage products comprise Carbavance, an antibiotic agent that has completed Phase III development stage for the treatment of hospitalized patients with serious gram-negative bacterial infections; Inclisiran, a synthesis inhibitor for the potential treatment of hypercholesterolemia; and MDCO-700, an intravenous anesthetic agent developed for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures. The Medicines Company has a collaboration agreement with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $1.77 bn
  • 3M gains: +65.98 %
  • Avg. Volume: 17.7 M

NxStage Medical, Inc. (NXTM)

NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure.Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $1.95 bn
  • 3M gains: +6.23 %
  • Avg. Volume: 4.3 M

Ra Pharmaceuticals, Inc. (RARX)

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States.The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The company's preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune\u002FCNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $658.65 M
  • 3M gains: +0.69 %
  • Avg. Volume: 4.5 M

Stellar Biotechnologies, Inc. (SBOT)

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia.The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $6.02 M
  • 3M gains: +25,921,500.00 %
  • Avg. Volume: 4.7 M

Teladoc Health, Inc. (TDOC)

Teladoc, Inc. operates a telehealth platform that provides on-demand healthcare services to its members in the United States.Its solution connects consumers with its physicians and behavioral health professionals that treat a range of conditions and cases, including acute diagnoses, such as upper respiratory infection, urinary tract infection, and sinusitis; dermatological conditions; anxiety; and smoking cessation. The company offers its services through mobile devices, the Internet, video, and phone. It serves employers of Fortune 1000 companies, health plans, health systems, and other entities. Teladoc, Inc. was founded in 2002 and is headquartered in Purchase, New York.

  • Industry: Medical/Nursing Services
  • Country: USA
  • Market cap: $4.67 bn
  • 3M gains: +96.95 %
  • Avg. Volume: 12.5 M

Forty Seven, Inc. (FTSV)

  • Industry: Major Pharmaceuticals
  • Country:
  • Market cap: $479.01 M
  • 3M gains: +114.64 %
  • Avg. Volume: 7.2 M

Insys Therapeutics, Inc. (INSY)

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $355 M
  • 3M gains: +1,424,220,000.00 %
  • Avg. Volume: 17.8 M

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products.It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccine to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $127.91 bn
  • 3M gains: +2.50 %
  • Avg. Volume: 21.3 M

Loxo Oncology, Inc. (LOXO)

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States.Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1\u002F2 trial, and an adult\u002Fadolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $7.22 bn
  • 3M gains: +49.92 %
  • Avg. Volume: 4.5 M

Masimo Corporation (MASI)

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide.The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation has a strategic partnership with NU Hospitals. The company was founded in 1989 and is headquartered in Irvine, California.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $6.83 bn
  • 3M gains: +12.25 %
  • Avg. Volume: 2.1 M

Molina Healthcare Inc (MOH)

Molina Healthcare, Inc. provides Medicaid-related solutions to meet the health care needs of low-income families and individuals; and to assist state agencies in their administration of the Medicaid program in the United States.It operates through three segments: Health Plans, Molina Medicaid Solutions, and Other. The Health Plans segment operates health plans in 12 states. As of December 31, 2016, this segment served approximately 4.2 million members who were eligible for Medicaid, Medicare, and other government-sponsored health care programs. The Molina Medicaid Solutions segment offers business process, information technology development, and administrative services to Medicaid agencies in Idaho, Louisiana, Maine, New Jersey, and West Virginia, as well as the U.S. Virgin Islands; drug rebate administration services in Florida; and other services, including hosting and support, and maintenance. The Other segment provides behavioral health and social services. The company offers health care services for its members through contracts with physicians, hospitals, and other providers. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.

  • Industry: Medical Specialities
  • Country: USA
  • Market cap: $8.49 bn
  • 3M gains: -0.68 %
  • Avg. Volume: 3.6 M

Abbott Laboratories (ABT)

  • Industry: Major Pharmaceuticals
  • Country:
  • Market cap: $129.92 bn
  • 3M gains: -14.33 %
  • Avg. Volume: 34.1 M

Allied Healthcare Products, Inc. (AHPI)

Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide.The company's respiratory care\u002Fanesthesia products comprise air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing products, facemasks, cannulas, and ventilator circuits; and home respiratory care products include aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, and portable suction equipment. It also provides medical gas equipment, which comprise construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers medical products that include respiratory\u002Fresuscitation products comprising demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products, such as spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. The company serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. Allied Healthcare Products, Inc. was founded in 1979 and is headquartered in St. Louis, Missouri.

  • Industry: Industrial Specialties
  • Country: USA
  • Market cap: $7.42 M
  • 3M gains: +1,470.91 %
  • Avg. Volume: 5.5 M

Alder BioPharmaceuticals, Inc. (ALDR)

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland.The company's lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis. In addition, the company has preclinical programs in the discovery phase for various indications. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $955.2 M
  • 3M gains: +81.02 %
  • Avg. Volume: 15.9 M

Altimmune, Inc. (ALT)

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, designs and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer.The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. Its preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others. The company was formerly known as Vaxin Inc. Altimmune, Inc. was founded in 1997 and is based in Gaithersburg, Maryland.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $26.17 M
  • 3M gains: +58.33 %
  • Avg. Volume: 5.9 M

Amgen Inc. (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar\u002FMimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $118.96 bn
  • 3M gains: -17.33 %
  • Avg. Volume: 14.5 M

Alpha Pro Tech, Ltd. (APT)

Alpha Pro Tech, Ltd. engages in developing, manufacturing, and marketing a line of disposable protective apparel, building supply products, and infection control products in the United States and internationally.The company operates through three segments: Building Supply, Disposable Protective Apparel, and Infection Control. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, gowns, coveralls, lab coats, frocks, and other miscellaneous products. The Infection Control segment offers face masks and eye shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private label. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is based in Markham, Canada.

  • Industry: Industrial Specialties
  • Country: Canada
  • Market cap: $49.43 M
  • 3M gains: +219.09 %
  • Avg. Volume: 25.4 M

ArQule, Inc. (ARQL)

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The company's clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine\u002Fthreonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of Bruton's tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. ArQule, Inc. also has a collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor in Greater China. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $350.95 M
  • 3M gains: +119.06 %
  • Avg. Volume: 20.3 M

Health Care sector performance

After sliding a chilling -14.62% in a week last week, Healthcare sector ETF closed this week at $84.99 and skyrocketed a super good 7.98%.

Not so far away is the last price record Healthcare sector ETF marked late January, but since then it dropped a 18.72%. Since early March, when XLV stock price broke down the 40-weeks moving avarage line, it slid $-11.69 per share (-12.09%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Since late May 2019 when SMA20w and SMA40w crossed up, XLV price slipped $-2.46 per share (-2.81%).

Healthcare sector ETF performance
3 months-16.50 %
6 months-3.38 %
1 year-5.13 %

Health Care sector industries

Industry
Biotechnology
Hospital/Nursing Management
Industrial Specialties
Major Pharmaceuticals
Medical Electronics
Medical Specialities
Medical/Dental Instruments
Medical/Nursing Services
Ophthalmic Goods
Other Pharmaceuticals
Precision Instruments

Novartis stock

The featured stock this month is Novartis, a leading pharma company that markets a range of healthcare products worldwide. Novartis stock made all-time highs last July, and since then the share has been sliding progressively and it's now down close to 10% from ATH.

Top performing stocks in the Health Care sector

Company3M gain6M gain
Aetna+6.47 %+21.07 %
Array+106.52 %+149.22 %
The Medicines+65.98 %+129.65 %
NxStage Medical+6.23 %+5.86 %